Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

Fig. 4

Status of G-CSF use. a treatment by cycle, b treatment by cycle in patients with FN, c onset of FN after cycle 2 according to the treatment received. * p value of the test for the null hypothesis “H0: Usage rate of pegfilgrastim after cycle 2 = 50%” versus the alternative hypothesis “H1: Usage rate of pegfilgrastim after cycle 2 ≠ 50%”. FN febrile neutropenia, G-CSF granulocyte colony-stimulating factor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us